SOUTH SAN FRANCISCO, Calif. & CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, today announced the appointment of Hugh Young Rienhoff, Jr., M.D., as Chairman of the Board, Charles A. Johnson, M.D., to the Board of Directors, and Alain Delcayre, Ph.D., as Senior Vice President of Research. “We are delighted to announce the ad….
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.